• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Covance, CORL collaborate for ocular drug development

Article

Covance and Comparative Ophthalmic Research Laboratories (CORL) announce their collaboration as a resource for ocular drug development.

Covance and Comparative Ophthalmic Research Laboratories (CORL) announce their collaboration as a resource for ocular drug development.

Covance provides testing services for the pharmaceutical and biotechnology industries. CORL is a collaborative team of internationally recognized vision scientists providing world-class vision research support for industry.

Having worked together for the past 10 years, the Covance/CORL alliance brings an unprecedented breadth of expertise and depth of knowledge to ocular drug development, the organizations said in a prepared joint statement.

Through the collaboration, the organizations are able to provide advanced ophthalmic techniques and complex study designs, Good Laboratory Practice-compliant studies, and close proximity for maximum study responsiveness.

For more information, visit Covance at Booth 614.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.